Comparison of Effects of Pitavastatin Versus Pravastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Statin-Naive Patients With Coronary Artery Disease

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein cholesterol levels. Although statins increase serum PCSK9 levels, the effects of different types of statins on the serum PCSK9 levels have not been examined in detail. The purpose of the present...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2013-05, Vol.111 (10), p.1415-1419
Main Authors: Nozue, Tsuyoshi, MD, Hattori, Hiroaki, PhD, Ishihara, Mitsuaki, MS, Iwasaki, Tadao, MS, Hirano, Tsutomu, MD, Kawashiri, Masa-aki, MD, Yamagishi, Masakazu, MD, Michishita, Ichiro, MD
Format: Article
Language:English
Subjects:
Aged
Apoptosis
Biomarkers - blood
Cardiovascular
Cardiovascular disease
Cholesterol
Coronary Artery Disease - blood
Coronary Artery Disease - drug therapy
Dose-Response Relationship, Drug
Enzyme-Linked Immunosorbent Assay
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Lipids
Low density lipoprotein
Male
Pravastatin - administration & dosage
Proprotein Convertase 9
Proprotein Convertases - blood
Prospective Studies
Proteins
Quinolines - administration & dosage
Serine Endopeptidases - blood
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein cholesterol levels. Although statins increase serum PCSK9 levels, the effects of different types of statins on the serum PCSK9 levels have not been examined in detail. The purpose of the present study was to compare the effects of pitavastatin versus pravastatin on the serum PCSK9 levels. A total of 164 patients with coronary artery disease who were not receiving lipid-lowering therapy were randomly assigned to receive either 4 mg/day of pitavastatin (intensive lipid-lowering therapy) or 20 mg/day of pravastatin (moderate lipid-lowering therapy). The serum PCSK9 levels were measured before statin treatment and 8 months after therapy. A significantly greater reduction in low-density lipoprotein cholesterol was observed in the pitavastatin group (−41% vs −28%, p = 0.0001). The serum levels of total PCSK9 and heterodimer PCSK9 significantly increased from 192 to 249 ng/ml (37%, p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2013.01.289